MERLIN

MEsenchymal stem cells to Reduce Liver INflammation

 Coordinatore THE UNIVERSITY OF BIRMINGHAM 

 Organization address address: Edgbaston
city: BIRMINGHAM
postcode: B15 2TT

contact info
Titolo: Ms.
Nome: May
Cognome: Chung
Email: send email
Telefono: 441214000000
Fax: 441214000000

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 7˙026˙727 €
 EC contributo 5˙382˙958 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-02-01   -   2018-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF BIRMINGHAM

 Organization address address: Edgbaston
city: BIRMINGHAM
postcode: B15 2TT

contact info
Titolo: Ms.
Nome: May
Cognome: Chung
Email: send email
Telefono: 441214000000
Fax: 441214000000

UK (BIRMINGHAM) coordinator 1˙624˙439.00
2    ORBSEN THERAPEUTICS LIMITED

 Organization address address: ORBSEN BUILDING NATIONAL UNIVERSITY OF IRELAND
city: GALWAY

contact info
Titolo: Dr.
Nome: Stephen
Cognome: Elliman
Email: send email
Telefono: +353 86 0285113

IE (GALWAY) participant 931˙516.00
3    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Titolo: Dr.
Nome: Carla
Cognome: Baan
Email: send email
Telefono: +31 107038293
Fax: +31 10 7044718

NL (ROTTERDAM) participant 732˙850.00
4    NHS BLOOD AND TRANSPLANT

 Organization address address: OAK HOUSE REEDS CRESCENT
city: WATFORD
postcode: WD24 4QN

contact info
Titolo: Dr.
Nome: Daniel
Cognome: Hollyman
Email: send email
Telefono: +44 01179757575
Fax: +0121 278 4149

UK (WATFORD) participant 682˙172.00
5    BIOINVISION INC

 Organization address address: BETA DRIVE 781 STE E
city: MAYFIELD VILLAGE OH
postcode: 44143

contact info
Titolo: Dr.
Nome: Debashish
Cognome: Roy
Email: send email
Telefono: +1 2163731500
Fax: +1 2162019375

US (MAYFIELD VILLAGE OH) participant 549˙031.00
6    UNIVERSITA DEGLI STUDI DI PADOVA

 Organization address address: VIA 8 FEBBRAIO 2
city: PADOVA
postcode: 35122

contact info
Titolo: Ms.
Nome: Luisa
Cognome: Caldon
Email: send email
Telefono: 390498000000

IT (PADOVA) participant 370˙105.84
7    PINTAIL LTD

 Organization address address: SPRINGHILL AVENUE 77
city: BLACKROCK

contact info
Titolo: Mr.
Nome: Ciaran
Cognome: Clissmann
Email: send email
Telefono: +353 12899529

IE (BLACKROCK) participant 327˙200.00
8    FONDAZIONE HUMANITAS PER LA RICERCA

 Organization address address: Via Manzoni 56
city: ROZZANO
postcode: 20089

contact info
Titolo: Dr.
Nome: Danilo
Cognome: Petroni
Email: send email
Telefono: +39 282242435

IT (ROZZANO) participant 165˙644.16
9    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Ms.
Nome: Renata
Cognome: Schaeffer
Email: send email
Telefono: 441223000000
Fax: 441223000000

UK (CAMBRIDGE) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

inflammatory    sub    diseases    inflammation    psc    marrow    cell    models    merlin    disease    liver    pre    msc       cells    clinical    pa    damage    safety    patients    mouse    efficacy    therapies   

 Obiettivo del progetto (Objective)

'Prevalence of liver disease is c6% (29 million people) in the EU with mortality rates from chronic liver diseases estimated at 14.3 per 100.000 in the EU-25 in 2004. Most liver diseases have a significant inflammatory component that underpins liver damage and fibrogenesis, yet current therapies have limited effectiveness. Safe novel anti-inflammatory therapies would satisfy a large unmet need for inflammatory liver conditions such as primary sclerosing cholangitis (PSC). Mesenchymal Stromal Cells (MSC) are a mixed population of plastic-adherent (PA) cells isolated from bone marrow, umbilical cord and adipose tissue. Preclinical studies show that intravenous administration of PA-MSC reduces liver inflammation/damage, however only one MSC-based clinical study has been reported to date. MERLIN will examine if MSC can safely reduce biliary damage in mouse models followed by a clinical study in patients with PSC. We have identified an antibody (S2) that isolates comparable MSC from human & mouse marrow, enabling testing of pure functionally distinct cell S2 & S2- and PA-MSC populations. We will use the world’s first GMP-compliant non-bead-based cell sorter to select S2 MSC to comply with future therapeutic regulatory requirements. MERLIN partners will use novel methods to enhance MSC efficacy in PSC - by reducing immune clearance of MSC & by promoting MSC functionality & localisation in vivo. We will assess if MSC sub-sets exert differing levels of control upon liver inflammation in pre-clinical models, as well as defining their proliferation and mechanism of action. We will develop entirely novel biomarkers for PSC within the disease pathway pre and post cell infusion. The optimal combination of MSC sub-set and “efficacy enhancement”, will be selected for progression to a Phase 2 clinical safety study in patients with PSC. MERLIN will deliver a comprehensive data-set on optimised purified MSC and their efficacy/safety in pre-clinical models prior to a clinical trial in patients with PSC.'

Altri progetti dello stesso programma (FP7-HEALTH)

PAR (2010)

Predicting antibiotic resistance

Read More  

ADAPT (2008)

Adipokines as Drug Targets to Combat Adverse Effects of Excess Adipose Tissue

Read More  

PREDEMICS (2011)

"Preparedness, Prediction and Prevention of Emerging Zoonotic Viruses with Pandemic Potential using Multidisciplinary Approaches"

Read More